Cigna Research Reveals Less Than 1 in 3 Americans Have Strong Sense of Purpose
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 day ago
0mins
Source: PRnewswire
- Purpose and Health: Cigna's research indicates that individuals with a strong sense of purpose report significantly higher vitality, better health, stronger relationships, and greater work engagement; however, the 2025 Vitality in America report reveals that fewer than one in three American adults claim to have a strong sense of purpose.
- Social Impact: This finding highlights a widespread lack of purpose among American adults, which could adversely affect overall societal health and work efficiency, suggesting a need for businesses and policymakers to focus on enhancing mental health and sense of purpose.
- Research Background: The report is based on a comprehensive survey of American adults aimed at revealing the impact of purpose on personal quality of life, emphasizing the importance of mental health in modern society.
- Future Outlook: Cigna may leverage these findings to promote related health initiatives aimed at enhancing public sense of purpose and quality of life, thereby strengthening its competitive position in the health insurance market.
CI.N$0.0000%Past 6 months

No Data
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 337.60 USD with a low forecast of 294.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 337.60 USD with a low forecast of 294.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 270.320

Current: 270.320

maintain
$309 -> $318
Reason
Guggenheim raised the firm's price target on Cigna to $318 from $309 and keeps a Buy rating on the shares.
BofA analysts added Cigna to the firm's "US 1 List," which represents a collection of its best investment ideas.
Market Perform
downgrade
$346 -> $294
Reason
Bernstein analyst Lance Wilkes lowered the firm's price target on Cigna to $294 from $346 and keeps a Market Perform rating on the shares following quarterly results. The firm is also adjusting its EPS model to reflect pressure in the PBM margin, with 2026 Evernorth earnings expected down 4% due to Pharmacy Benefit Services subsegment margin declining by an estimated 17%, offset by growth in the specialty segment and Cigna Healthcare.
downgrade
$370 -> $330
Reason
Goldman Sachs analyst Scott Fidel lowered the firm's price target on Cigna to $330 from $370 and keeps a Buy rating on the shares.
About CI
The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.